
Pioneering Science for Patient Choice
Advancing new oral alternatives for all people living with hereditary angioedema (HAE)
View our Science
Pharvaris aims to develop novel, oral alternatives that improve the standard of care for people living with HAE.
View our Pipeline
HAE CHAPTER-3
Pivotal Phase 3 study of deucrictibant for the prophylactic treatment of HAE attacks

RAPIDe-3
Pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks
Pharvaris is a leader in bradykinin-mediated diseases, aiming to deliver effective, safe and easy to administer therapies.
View our Science
Pharvaris is committed to improving the treatment of HAE and the quality of life for people living with HAE.
HAE CommunityOur legacy in HAE, our scientific expertise, and our values drive our passion as we aspire to provide choice to people living with HAE.
About Us